Macrocyclics introduces new products

January 10, 2014

Macrocyclics, Inc. (an AREVA Med company) announced today the introduction of four new products that will expand PET imaging applications with copper-64 and gallium-68 using NOTA-based chelating platforms. In addition, a new serotonin-based DOTA conjugate offers the potential to image serotoninergic neurotransmission using a radioisotope or with gadolinium by magnetic resonance imaging (MRI).

 Please visit  http://www.macrocyclics.com for detailed information.

Video

AREVA Med:  Developing Nuclear Medicine for Tomorrow’s Cancer Treatments

The goal of AREVA Med’s lead-212 research is to create personalized treatments using targeted immunotherapy.  Using this biomedical innovation, cancer cells are specifically targeted and destroyed by a vector radiolabeled with lead-212, without harming nearby healthy cells.

AREVA Med Video

Click here to view the latest AREVA Med Video

Contact

For more information about AREVA Med, please contact:
Alison Tise
Tel.: + 1 (301) 841-1673